share_log
Reuters ·  Apr 8 07:00
J&J - up to 128 Weeks & 180 Patient Years of Follow-up in Open-Label Extension(a) Confirm Safety Profile Consistent With Phase 3 Vivacity-Mg3 Study
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 244

Recommended

Write a comment